53 House LLP Buys New Shares in Humana Inc. $HUM

Key Points

• 53 House LLP has made significant investments in Humana Inc. by acquiring 36,921 shares valued at approximately $9.77 million, which represents about 8.6% of its total portfolio.
• Humana's stock has seen various analyst ratings, with a consensus rating of "Hold" and a target price of $283.29 after several upgrades and downgrades from firms such as Morgan Stanley and Royal Bank of Canada.
• The company recently declared a quarterly dividend of $0.885 per share, yielding 1.2%, illustrating its commitment to returning value to shareholders despite mixed earnings results.

53 House LLP purchased a new stake in shares of Humana Inc. (NYSE:HUM - Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 36,921 shares of the insurance provider's stock, valued at approximately $9,769,000. Humana makes up about 8.6% of 53 House LLP's portfolio, making the stock its 6th largest holding.

Other large investors have also added to or reduced their stakes in the company. Deutsche Bank AG grew its position in Humana by 18.2% in the 4th quarter. Deutsche Bank AG now owns 631,371 shares of the insurance provider's stock worth $160,185,000 after purchasing an additional 97,071 shares during the period. Janney Montgomery Scott LLC bought a new stake in Humana in the 1st quarter worth approximately $1,309,000. Fred Alger Management LLC bought a new stake in Humana in the 4th quarter worth approximately $451,000. Clearline Capital LP bought a new stake in Humana in the 4th quarter worth approximately $1,102,000. Finally, Envestnet Asset Management Inc. grew its position in Humana by 2.4% in the 1st quarter. Envestnet Asset Management Inc. now owns 125,684 shares of the insurance provider's stock worth $33,256,000 after purchasing an additional 2,950 shares during the period. Institutional investors own 92.38% of the company's stock.

Humana Stock Performance

Shares of HUM stock traded down $1.57 during mid-day trading on Wednesday, reaching $297.30. 859,256 shares of the company's stock traded hands, compared to its average volume of 1,782,731. Humana Inc. has a 12 month low of $206.87 and a 12 month high of $382.72. The firm has a 50 day moving average price of $250.98 and a two-hundred day moving average price of $253.78. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.95 and a current ratio of 1.95. The firm has a market capitalization of $35.76 billion, a PE ratio of 22.82, a price-to-earnings-growth ratio of 1.76 and a beta of 0.44.

Humana (NYSE:HUM - Get Free Report) last issued its quarterly earnings data on Wednesday, July 30th. The insurance provider reported $6.27 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $6.32 by ($0.05). Humana had a net margin of 1.28% and a return on equity of 13.67%. The business had revenue of $32.39 billion for the quarter, compared to the consensus estimate of $31.85 billion. During the same period in the previous year, the firm earned $6.96 EPS. The company's revenue was up 9.6% on a year-over-year basis. Humana has set its FY 2025 guidance at 17.000- EPS. On average, research analysts forecast that Humana Inc. will post 16.47 EPS for the current year.

Humana Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Friday, September 26th will be paid a dividend of $0.885 per share. The ex-dividend date is Friday, September 26th. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.2%. Humana's payout ratio is 27.17%.

Analyst Ratings Changes

A number of research firms have commented on HUM. Truist Financial cut their target price on shares of Humana from $280.00 to $260.00 and set a "hold" rating for the company in a research report on Wednesday, July 16th. Oppenheimer lifted their target price on shares of Humana from $300.00 to $310.00 and gave the stock an "outperform" rating in a research report on Thursday, May 1st. Piper Sandler cut their target price on shares of Humana from $288.00 to $272.00 and set a "neutral" rating for the company in a research report on Thursday, July 31st. Morgan Stanley cut their target price on shares of Humana from $290.00 to $277.00 and set an "equal weight" rating for the company in a research report on Thursday, July 31st. Finally, Cantor Fitzgerald reissued a "neutral" rating and set a $290.00 price objective on shares of Humana in a research report on Thursday, May 1st. Seven research analysts have rated the stock with a Buy rating and sixteen have issued a Hold rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Hold" and an average target price of $283.29.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.